«

»

Jul 22

Treating HFrEF with sacubitril/valsartan reduces all-cause and heart-failure readmissions

Findings based on data from the Prospective Comparison of ARNI With an ACE-Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial show that treating patients with heart failure and reduced ejection fraction (HFrEF) with the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan (Entresto, Novartis) led to a 26% lower rate of 30-day readmission for any cause and a 38% lower rate of 30-day readmission for HF vs those treated with the ACE inhibitor enalapril. The study is published online July 11 in the Journal of the American College of Cardiology.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>